| Kimberly Garko |
Kimberly Garko is currently the Chief Technical Officer & Senior Vice President at Akebia Therapeutics, Inc. Prior to her current position, she worked as the Director-Global Quality Systems at Stryker Corp. from 2018 to 2020. Before that, she served as the Vice President-Quality at Eversana Life Science Services LLC in 2016 and 2017. From 2002 to 2015, she held the position of Head-Quality at Biogen, Inc. Dr. Garko holds a graduate degree from the University of South Florida and a doctorate degree from Louisiana State University. |
| Steven K. Burke |
Steven K. Burke is currently a Director at LeukoSight, Inc. and AbFero Pharmaceuticals, Inc. He is also the Chief Medical Officer & SVP-Research & Development at Akebia Therapeutics, Inc. He previously worked as the Medical Director & VP-Clinical Research at GelTex Pharmaceuticals, Inc. and as an Associate Director-Clinical Research at Glaxo, Inc. He was also the Chief Medical Officer & Senior Vice President at Proteon Therapeutics, Inc. from 2006 to 2019 and the Chief Medical Officer at Protara Therapeutics, Inc. He holds a doctorate from Weill Cornell Medical College and an undergraduate degree from Harvard College. |
| Nicole R. Hadas |
Nicole R. Hadas is currently the Secretary, Chief Legal Officer & Senior VP at Akebia Therapeutics, Inc. She previously worked as the President & Secretary at Keryx Biopharmaceuticals, Inc. and as the Senior Corporate Counsel at Genzyme Corp. She also served as the Senior Vice President & General Counsel at Inspiration Biopharmaceuticals, Inc. and as an Associate at Foley Hoag LLP. Additionally, she held the position of Vice President & General Counsel at OvaScience, Inc. Ms. Hadas obtained her undergraduate degree from the University of Michigan and her graduate degree from Boston College Law School. |
| Michel Dahan |
Michel Dahan is currently the Director at Alkeus Pharmaceuticals, Inc. since 2023 and the Chief Operating Officer & Senior Vice President at Akebia Therapeutics, Inc. since 2013. Previously, he worked as the Director-International Product at Ipsen, Inc. from 2003 to 2010 and as the VP-Commercial Development & Strategic Planning at Inspiration Biopharmaceuticals, Inc. from 2010 to 2013. Mr. Dahan holds a graduate degree from Université Pierre et Marie Curie and an undergraduate degree from École des Hautes Études Commerciales de Paris. |
| Nicholas Grund |
Nicholas Grund is currently the Chief Commercial Officer at Akebia Therapeutics, Inc. He previously held positions as the Head-Specialty Care at Genzyme Corp from 2007 to 2015, the Chief Commercial Officer & Executive VP at AMAG Pharmaceuticals, Inc. from 2016 to 2019, and as the President-Eurofins at Transplant Genomics, Inc. from 2021 to 2022. Mr. Grund also worked as a Principal at Bayer Diagnostics Corp. from 1995 to 2002. He holds an MBA from Northeastern University and an undergraduate degree from the University of Massachusetts. |
| Richard C. Malabre |
Richard C. Malabre is currently the Chief Accounting Officer at Akebia Therapeutics, Inc. Prior to this, he was the Chief Financial Officer & Treasurer at Ultivue, Inc. from 2021 to 2023. Malabre has a graduate degree from the Massachusetts Institute of Technology and an undergraduate degree from Trinity College (Connecticut). |
| Adrian Adams |
Adrian Adams is currently the Chairman at Akebia Therapeutics, Inc. since 2018 and the Chairman at Talphera, Inc. since 2013. Previously, he served as the President & Chief Executive Officer at Sumitomo Pharma America, Inc. from 2007 to 2010, Chairman & Chief Executive Officer at Neurologix, Inc. in 2011, President & Chief Executive Officer at KOS Pharmaceuticals, Inc. from 2002 to 2006, President, Chief Executive Officer & Director at Inspire Pharmaceuticals, Inc. in 2011, Chief Executive Officer & Director at POZEN, Inc. from 2015 to 2016, President, Chief Executive Officer & Director at Auxilium Pharmaceuticals LLC from 2011 to 2015, Chief Executive Officer & Director at Old API Wind-down Ltd. from 2016 to 2019, Chief Executive Officer & Director at Aralez Pharmaceuticals Plc from 2015 to 2019, Independent Director at Amylin Pharmaceuticals, Inc. from 2011 to 2012, Director at Neurocrine Biosciences, Inc. from 2005 to 2007, and Director-Sales & Marketing at AstraZeneca, Inc. He also held the position of President & Chief Executive Officer at Novartis Pharmaceuticals UK Ltd. from 1999 to 2001. Mr. Adams received his undergraduate degree from The University of Manchester and the University of Salford. |
| Michael Rabinowitz |
Michael Rabinowitz currently works at Akebia Therapeutics, Inc., as Vice President-Research. |
| John P. Butler |
John P. Butler's current job is President, CEO, Chief Financial Officer & Director at Akebia Therapeutics, Inc. Mr. Butler's former jobs include Chief Executive Officer at Inspiration Biopharmaceuticals, Inc. (2011), Chairman at American Kidney Fund, Inc. (2013-2015), Chairman at Kidney Care Partners, Director at Keryx Biopharmaceuticals, Inc. (2015-2017), Independent Director at Zynerba Pharmaceuticals, Inc. (2018-2023), Independent Director at Relypsa, Inc. (2013-2016), and Product Manager at Amgen, Inc. (1995-1997). He also served as SVP & President-Cardiometabolic & Renal at Genzyme Corp. (2009-2011) and Head-Sales & Marketing at Hoffmann-La Roche, Inc.Mr. Butler's education includes an undergraduate degree from Manhattan College and an MBA from Baruch College. |
| Michael W. Rogers |
Michael W. Rogers is an Independent Director at Akebia Therapeutics, Inc. He previously served as the Chairman at Keryx Biopharmaceuticals, Inc. and as an Independent Director at Fortress Biotech, Inc., Aravive, Inc., EyePoint Pharmaceuticals, Inc., and Indevus Pharmaceuticals, Inc. He also held positions as Vice President-Investment Banking at Lehman Brothers, Inc. and PaineWebber, Inc. Additionally, he served as the Chief Financial Officer, Treasurer & Executive VP at Indevus Pharmaceuticals, Inc., AutoImmune, Inc., AHT Corp., Acorda Therapeutics, Inc., and BG Medicine, Inc. He obtained his undergraduate degree from Union College (New York) and an MBA from the University of Virginia Darden School of Business. |
| Myles Wolf |
Myles Wolf is currently the Chairman-North American Region at World Kidney Fund - International Society of Nephrology, an Independent Director at Akebia Therapeutics, Inc., and a Professor at Duke University School of Medicine. He has an undergraduate degree from The Johns Hopkins University, a doctorate from Harvard Medical School, and a graduate degree from The State University of New York. |
| LeAnne M. Zumwalt |
LeAnne M. Zumwalt is an Independent Director at Akebia Therapeutics, Inc. and a Director at ADPT DFW Holdings LLC. She was an Independent Director at The Advisory Board Co. from 2001 to 2017, a Director at Adeptus Health, Inc. from 2018 to 2020, the Chief Financial Officer & Treasurer at Dialysis Holdings, Inc. from 1991 to 1997, and the Group Vice President-Government Affairs at DaVita, Inc. from 2011 to 2021. She was also a Senior Manager at Ernst & Young LLP and the Chief Financial Officer at Vivra Specialty Partners, Inc. from 1997 to 1999. Ms. Zumwalt received an undergraduate degree from Pacific Union College. |
| Cynthia Smith |
Cynthia Smith is an Independent Director at Agios Pharmaceuticals, Inc., Akebia Therapeutics, Inc., Spero Therapeutics, Inc., and Protara Therapeutics, Inc. She is also a Director at French-American Foundation. In the past, she worked as an Executive Director-Healthcare System at Merck & Co., Inc., Chief Commercial Officer at ZS Pharma, Inc., and VP-Market Access & Commercial Development at Affymax, Inc. She also served as an Independent Director at Dicerna Pharmaceuticals, Inc. and Nivalis Therapeutics, Inc. Ms. Smith has an undergraduate degree from The University of North Carolina at Chapel Hill, an MBA from The Wharton School of the University of Pennsylvania, and a graduate degree from Eagleton Institute of Politics. |
| Ronald E. Frieson |
Ronald E. Frieson is currently serving as the Chairman at The University of Tennessee Foundation, Inc., Director at American InterContinental University System, Inc., Director at Children's Healthcare of Atlanta Surgery Center At Meridian, Director at Colorado Technical University, Inc., Independent Director at Akebia Therapeutics, Inc., Director at 100 Black Men of Atlanta, Inc., and Chief Operating Officer at Children's Healthcare of Atlanta, Inc. He previously held positions as the Interim President & Chief Executive Officer at Urban League of Atlanta, Director at Georgia Chamber of Commerce, Director at Atlanta-Fulton County Zoo, Inc., Director at Hands on Atlanta, Director at SunTrust Bank (Atlanta, Georgia), Director at Atlanta Police Foundation, President-Georgia Operations at BellSouth LLC, President-Georgia Operations at AT&T, Inc., Member at Leadership Atlanta, Inc., Trustee at American Kidney Fund, Inc., and Trustee at Children's Miracle Network. Mr. Frieson completed his undergraduate degree at the University of Tennessee. |
| Steven C. Gilman |
Steven C. Gilman is an Independent Director at Vericel Corp., SCYNEXIS, Inc., and Akebia Therapeutics, Inc. He is also a Director at Biotechnology Association of Alabama, Massachusetts Society for Medical Research, Inc., PhRMA Foundation, Transcelerate Biopharma, Inc., and Lakes Environmental Association. Previously, he served as Chairman & Chief Executive Officer at ActivBiotics, Inc., Vice Chairman at ContraFect Corp., Biology Director at Jazz Pharmaceuticals (EUSA Pharma USA), Inc., Independent Director at Keryx Biopharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc., Group Director-Global Research & Development at Pfizer (St. Louis), Executive Director at Inhibikase Therapeutics, Inc., Scientist at Wyeth LLC, Vice President & General Manager-Inflammation at Millennium Pharmaceuticals, Inc., and Chief Scientific Officer & Executive VP-Research at Cubist Pharmaceuticals LLC. He also served as a Principal at Connecticut College, Inflammation Research Association, Inc., and Temple University School of Medicine. He received his undergraduate degree from Miami University and his graduate and doctorate degrees from The Pennsylvania State University. |
